| |
Protocol Number:
01-C-0235
- Title:
Combination Antibody Therapy with Apolizumab (1D10) and Rituximab (CD20) in Relapsed Lymphoma and CLL
- Number:
01-C-0235
- Summary:
This study will evaluate the safety and effectiveness of a combination of two antibodies, apolizumab and rituximab (Rituxan® (Registered Trademark)), in treating B-cell lymphomas and chronic lymphocytic leukemia. Rituximab attaches to a molecule called CD20 on B-cell lymphomas and can cause significant shrinkage of these tumors in up to half of patients. However, it does not cure the lymphoma, which usually returns. Also, it is not as effective against leukemia. Apolizumab attaches to a protein called 1D10 on B-cell cancers and has also been able to shrink tumors in some patients. There is little experience apolizumab in patients with leukemia. This study will test whether the two antibodies together are more effective against these tumors than either one alone.
Patients 18 years and older with B-cell lymphoma or chronic lymphocytic leukemia may be eligible for this study. Patients' leukemia or lymphoma cells must have both the CD20 and 1D10 antigen receptors and must have had at least one systemic treatment for their disease. Candidates are screened with a medical history and physical examination, blood and urine tests, electrocardiogram, x-rays and other imaging studies, and possibly a bone marrow aspirate (withdrawal of a small marrow sample through a needle inserted into the hip bone) and lumbar puncture (withdrawal of a small sample of cerebrospinal fluid-fluid that bathes the brain and spinal cord-through a needle placed between the bones in the lower back).
Participants receive infusions of rituximab and apolizumab once a week for 4 weeks. The first patients in the study receive lower doses of apolizumab with standard doses of rituximab. If the apolizumab is well tolerated, subsequent patients are given higher doses. Patients are also given dexamethasone or another similar steroid, diphenhydramine (Benadryl® (Registered Trademark)), and acetominophen (Tylenol® (Registered Trademark)) to reduce reactions to the antibodies. After 4 weeks of treatment, patients are followed frequently to examine the response to treatment and evaluate drug side effects. Patients whose tumors do not grow during the 4 weeks of therapy may be offered another course of treatment at a later time. Participants are followed periodically after treatment ends until their disease worsens or the study ends.
- Sponsoring Institute:
-
National Cancer Institute (NCI)
- Recruitment Detail
- Type:
No longer recruiting/follow-up only
- Gender:
Male & Female
- Referral Letter Required:
No
- Population Exclusion(s):
None
- Eligibility Criteria:
This study is not currently recruiting new subjects. If you have questions about participating in a study, please contact the Patient Recruitment and Public Liaison Office, CC.
- Special Instructions:
Currently Not Provided
- Keyword(s):
-
HU 1D10
-
Rituximab
-
Lymphoma
-
Monoclonal Antibody
- Recruitment Keyword(s):
-
Lymphoma
-
Non-Hodgkin's Lymphoma
-
NHL
-
Chronic Lymphocytic Leukemia
-
CLL
-
Leukemia
- Condition(s):
-
Non-Hodgkin's Lymphoma
-
Chronic Lymphocytic Leukemia
- Investigational Drug(s):
-
MoAb: HU 1D10 (Apolizumab)
- Investigational Device(s):
- None
- Interventions:
-
Drug: MoAb: HU 1D10 (Apolizumab)
-
Drug: Ritoximab
- Supporting Site:
-
National Cancer Institute
- Contact(s):
-
This study is not currently recruiting new subjects. If you have questions about participating in a study, please contact the Patient Recruitment and Public Liaison Office, CC.
- Citation(s):
-
Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies
-
Inroads in the therapy of indolent lymphomas: exploiting biological insights
-
Monoclonal antibody therapy of cancer
If you have:
Search The Studies | Help | Questions |
Clinical Center Home | NIH Home
 National Institutes of Health Clinical Center
Bethesda, Maryland 20892. Last update: 01/13/2009
|
|
